List of Excipients in Branded Drug ACEBUTOLOL HYDROCHLORIDE

« Back to Dashboard

Generic Drugs Containing ACEBUTOLOL HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	acebutolol hydrochloride	0378-1200	D&C RED NO. 28
Mylan Pharmaceuticals Inc	acebutolol hydrochloride	0378-1200	D&C YELLOW NO. 10
Mylan Pharmaceuticals Inc	acebutolol hydrochloride	0378-1200	FD&C BLUE NO. 1
Mylan Pharmaceuticals Inc	acebutolol hydrochloride	0378-1200	FD&C BLUE NO. 2
Mylan Pharmaceuticals Inc	acebutolol hydrochloride	0378-1200	FD&C RED NO. 40
Mylan Pharmaceuticals Inc	acebutolol hydrochloride	0378-1200	FERROSOFERRIC OXIDE
Mylan Pharmaceuticals Inc	acebutolol hydrochloride	0378-1200	GELATIN

What are the Most Frequently-Used Excipients in ACEBUTOLOL HYDROCHLORIDE?

# Of NDCs	Excipient
2	AMMONIA
2	CARBOXYMETHYLCELLULOSE
2	D&C RED NO. 28
2	D&C YELLOW NO. 10
9	FD&C BLUE NO. 1
1	FD&C BLUE NO. 2
4	FD&C RED NO. 40

Acebutolol Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: October 29, 2026

Acebutolol hydrochloride is an established small-molecule beta-1 selective adrenergic blocker marketed primarily as immediate-release oral capsules in 200 mg and 400 mg strengths. Its commercial opportunity is not based on new-molecule exclusivity. It depends on reliable low-cost manufacture, differentiated capsule presentation, supply continuity, fixed-dose combinations, geriatric usability, and potential reformulation into longer-acting or adherence-oriented products.

The most defensible formulation strategy is a conventional hard-gelatin or hypromellose capsule containing a stable, rapidly dissolving powder blend. The main technical risks are powder flow, dose uniformity, moisture control, capsule-fill consistency, and preservation of rapid dissolution. Acebutolol hydrochloride has no biosimilar pathway because it is a chemically synthesized small molecule.

What is acebutolol hydrochloride used for?

Acebutolol hydrochloride is an oral beta-adrenergic receptor blocker used for hypertension and ventricular arrhythmias. The reference product, Sectral, was supplied as 200 mg and 400 mg capsules. Acebutolol has beta-1 selectivity at lower doses and intrinsic sympathomimetic activity. Its active metabolite, diacetolol, contributes to pharmacologic activity and has a longer half-life than the parent compound.[1]

Attribute	Acebutolol hydrochloride
Therapeutic class	Beta-adrenergic blocker
Primary indications	Hypertension; ventricular arrhythmias
Dosage form	Immediate-release oral capsule
Common strengths	200 mg and 400 mg
Active ingredient	Acebutolol hydrochloride
Molecular category	Small molecule
Biosimilar pathway	Not applicable
Main generic pathway	Abbreviated New Drug Application
Commercial reference	Sectral and generic acebutolol capsules

The product is administered orally and is typically supplied in multiple-dose bottles. That packaging format makes moisture protection, capsule-shell stability, and low-cost high-throughput filling central to commercial performance.

What excipients are used in acebutolol hydrochloride capsules?

Acebutolol hydrochloride capsules generally use conventional oral solid-dose excipients. Publicly available product labels identify inactive ingredients that may include lactose, microcrystalline cellulose, starch, magnesium stearate, colloidal silicon dioxide, gelatin, titanium dioxide, and capsule colorants, although the exact composition varies by manufacturer and strength.[2,3]

Formulation function	Common excipient options	Commercial purpose
Diluent	Lactose monohydrate, microcrystalline cellulose, mannitol	Adjust fill weight and improve manufacturability
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Promote capsule-plug breakup
Binder	Povidone, pregelatinized starch	Improve granule or compact strength
Glidant	Colloidal silicon dioxide	Improve powder flow and fill-weight control
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduce ejection and equipment adhesion
Moisture-control excipient	Microcrystalline cellulose, selected low-moisture grades	Improve physical stability
Capsule shell	Gelatin or hypromellose	Provide dose containment and product identification
Opacifier or colorant	Titanium dioxide, iron oxides, approved dyes	Brand differentiation and light protection
Taste or odor control	Capsule shell, opaque packaging	Improve patient acceptability

The label for one generic product should not be treated as the industry standard. Excipient selection differs with API particle size, bulk density, supplier capability, capsule machine, target fill weight, and dissolution profile.

Which excipients are most suitable for a commercial formulation?

A practical first-generation formulation would use acebutolol hydrochloride with microcrystalline cellulose, a superdisintegrant, colloidal silicon dioxide, and magnesium stearate in a hard capsule. This approach minimizes process complexity while supporting rapid disintegration.

Lactose can reduce cost and improve bulk handling, but it creates two commercial considerations. First, lactose intolerance claims may influence product selection even though the quantity in a capsule is usually small. Second, lactose can complicate moisture and compatibility assessments depending on the formulation process and storage environment.

Microcrystalline cellulose is a strong platform excipient because it supports direct blending, improves content uniformity, and is available in several particle-size grades. Crospovidone or croscarmellose sodium can provide rapid disintegration without requiring a complex granulation process. Colloidal silicon dioxide is useful where the API blend has poor flow or electrostatic behavior.

Magnesium stearate remains a cost-effective lubricant, but excessive blending can reduce wetting and slow dissolution. Lubricant concentration and blending time should therefore be controlled as critical process parameters.

How should acebutolol hydrochloride be formulated?

The preferred development sequence is a direct-blend or dry-granulation capsule platform, followed by dissolution and stability optimization.

Direct-blend capsule strategy

Direct blending is commercially attractive because it reduces equipment, processing time, and scale-up risk. The development program should assess:

• API particle-size distribution
• Bulk and tapped density
• Angle of repose and flow rate
• Electrostatic charging
• Segregation during transfer
• Blend uniformity
• Capsule-fill-weight variability
• Dissolution across physiologic pH conditions

If the API has acceptable flow and compressibility, direct filling can provide the lowest-cost process. If the API segregates from the excipient blend, dry granulation or roller compaction may improve uniformity.

Dry-granulation strategy

Dry granulation is useful where the API has poor flow, low bulk density, or a high tendency to segregate. It avoids water and organic solvents, which can simplify stability control. The principal risks are over-compaction, slower disintegration, excessive fines, and dissolution drift.

For acebutolol hydrochloride, dry granulation should be used only if direct blending cannot meet content-uniformity and filling requirements. The reference product is an immediate-release capsule, so any granulation step must preserve rapid release.

Wet-granulation strategy

Wet granulation can improve flow and content uniformity but adds process stages and residual-moisture controls. It is less attractive for a low-margin mature generic unless the formulation requires it. Aqueous granulation may also create avoidable stability work if the API or excipient system is moisture-sensitive.

What formulation patents could protect acebutolol hydrochloride products?

The strongest practical protection for a new acebutolol product would generally come from formulation, delivery, or manufacturing claims rather than the expired composition-of-matter estate.

Potential claim categories include:

1. Modified-release capsules or multiparticulate systems.
2. Once-daily delivery using coated pellets or matrix particles.
3. Taste-masked oral granules or sprinkle capsules.
4. Low-moisture formulations with defined dissolution performance.
5. Fixed-dose combinations with another antihypertensive.
6. Abuse-deterrent or controlled-delivery systems, although the commercial rationale is limited for acebutolol.
7. Manufacturing processes that improve content uniformity or reduce impurity formation.
8. Capsule-shell or packaging systems that improve photostability or humidity resistance.

A patent would need more than a routine excipient substitution. A commercially defensible claim should connect the excipient system to a measurable result, such as a defined dissolution profile, improved stability, reduced variability, enhanced bioavailability, or a clinically meaningful dosing advantage.

When does acebutolol hydrochloride lose exclusivity?

Acebutolol hydrochloride is a mature generic drug. The original product and conventional immediate-release formulation are no longer protected by meaningful new-molecule exclusivity in the U.S. The relevant market-entry issues are therefore manufacturing approval, bioequivalence, product availability, and any unexpired patent claims directed to a specific formulation or use.

Exclusivity category	Commercial status
New chemical entity exclusivity	Expired
Original composition-of-matter protection	Expired or commercially irrelevant
Conventional immediate-release capsule	Generic competition established
Biosimilar exclusivity	Not applicable
New formulation exclusivity	Possible only for a separately approved product
Pediatric exclusivity	Not a current barrier to ordinary generic entry
Reference-product exclusivity	Not a material barrier for the mature product

The exact Orange Book patent and exclusivity fields must be reviewed against the current FDA listing for the specific reference product and dosage form. FDA’s Orange Book identifies approved products, therapeutic equivalence evaluations, patent information, and exclusivity data.[4]

What is the Orange Book status of acebutolol hydrochloride?

Acebutolol hydrochloride is regulated as a small-molecule prescription drug. Generic manufacturers typically rely on an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the listed reference product.

The principal regulatory requirements are:

• Same active ingredient and dosage form
• Equivalent strength
• Pharmaceutical equivalence
• Bioequivalence
• Compliance with current good manufacturing practice
• Adequate labeling
• Acceptable stability data
• Demonstration of appropriate container-closure performance

Because acebutolol is an immediate-release capsule, an ANDA product would generally be evaluated through standard pharmacokinetic bioequivalence methods. Dissolution testing remains important for batch release, formulation development, post-approval changes, and comparison with the reference product.[5]

Are there Paragraph IV challenges for acebutolol hydrochloride?

Paragraph IV litigation risk is low for the legacy immediate-release product because the principal commercial barriers are no longer centered on a new active-ingredient patent estate. A Paragraph IV certification could still arise if a listed patent covers a particular reference formulation, method of use, or other protected feature.

For a conventional generic acebutolol capsule, the more important risk variables are:

• Whether the reference product has active listed patents
• Whether the ANDA applicant seeks approval for all labeled uses
• Whether a formulation patent is listed
• Whether a first-filer opportunity exists
• Whether the reference product remains commercially available
• Whether the applicant can obtain a therapeutically equivalent rating

Any historical litigation involving acebutolol should be separated from current market-entry exposure. Old patent disputes do not establish a current blocking right.

How strong is the acebutolol hydrochloride patent estate?

The patent estate is weak for the conventional immediate-release product and potentially stronger for a genuinely differentiated delivery system.

Asset type	Relative strength	Reason
Original molecule	Low	Mature compound with expired primary protection
Standard capsule formulation	Low	Routine formulation and established generic practice
Novel extended-release system	Moderate	Potentially protectable if technically differentiated
Fixed-dose combination	Moderate	Depends on combination, dosing, and clinical evidence
Manufacturing process	Low to moderate	Stronger if impurity control or scale performance is unexpected
Pediatric or sprinkle formulation	Moderate	Depends on patient benefit and claim scope
Packaging and moisture-control system	Low	Usually vulnerable to obviousness challenges

A formulation patent should be designed around reproducible product attributes. Broad claims covering any capsule containing acebutolol and a conventional filler are vulnerable to obviousness and anticipation challenges.

What commercial opportunities exist for acebutolol hydrochloride?

Low-cost generic supply

The most immediate opportunity is dependable supply of 200 mg and 400 mg capsules. Shortages, manufacturer exits, or limited supplier participation can create price opportunities even when long-term margins are low.

A competitive generic should prioritize:

• Two-dose-strength portfolio coverage
• High manufacturing yield
• Multiple API suppliers where qualified
• Automated capsule filling
• Robust dissolution across lots
• Multi-market packaging flexibility
• Low-cost bottle and label configurations

Contract manufacturing and private-label supply

Acebutolol is suitable for contract manufacturing because it is an established capsule product with a relatively simple dosage form. A manufacturer with unused oral-solid-dose capacity could offer private-label supply to regional distributors, hospital systems, and specialty wholesalers.

The commercial advantage would come from supply reliability, low minimum order quantities, and regulatory support rather than molecule differentiation.

Extended-release reformulation

A once-daily formulation could improve adherence relative to multiple daily dosing. Potential technologies include coated pellets, hydrophilic matrices, multiparticulates, and osmotic systems.

The opportunity is technically plausible but commercially uncertain. A reformulation would require:

• A clinically relevant dosing advantage
• Pharmacokinetic bridging
• A controlled-release profile
• New stability and manufacturing data
• A clear reimbursement rationale
• Protection against substitution by low-cost immediate-release generics

Without a meaningful reduction in dosing frequency or adverse-effect burden, a premium extended-release product may not justify development cost.

Sprinkle or geriatric formulation

A capsule that can be opened and sprinkled onto soft food could target patients with dysphagia, nursing-home populations, and certain geriatric settings. The formulation must preserve dose uniformity, stability, and rapid release after opening.

This opportunity would require careful instructions and compatibility testing with food vehicles. It could support a formulation patent if the delivery system offers a measurable stability or administration benefit.

Fixed-dose combinations

Combination products with diuretics, calcium-channel blockers, or renin-angiotensin-system agents could improve pill burden. The commercial case depends on current treatment guidelines, prescriber familiarity, and whether acebutolol remains clinically preferred for the target population.

Combination-product development also creates regulatory complexity. Each component’s dosage, interaction profile, and labeling must support the proposed indication.

What manufacturing and intellectual-property barriers apply?

The manufacturing barrier is moderate rather than high. Acebutolol hydrochloride capsules do not require sterile processing, biologic control systems, or complex device assembly. The main barriers are quality-system execution and reliable product performance.

Critical quality attributes

Relevant critical quality attributes include:

• Assay
• Content uniformity
• Related substances
• Water content
• Capsule-fill weight
• Dissolution
• Disintegration
• Microbial quality
• Stability under long-term and accelerated conditions

Critical process parameters

Key process parameters include:

• Blending time
• Lubrication time
• Granulation force, if applicable
• Screen size
• Transfer speed
• Capsule-filling settings
• Environmental humidity
• Hold time before encapsulation

A manufacturer seeking global registration should also assess regional excipient restrictions, capsule-shell requirements, colorant permissions, nitrosamine risk assessments, and packaging standards.

How does acebutolol compare with competing beta blockers?

Acebutolol competes with established beta blockers including metoprolol, atenolol, bisoprolol, propranolol, and carvedilol.

Product	Main commercial distinction	Generic pressure	Reformulation opportunity
Acebutolol	Beta-1 selectivity with intrinsic sympathomimetic activity	High	Moderate
Metoprolol	Broad use; immediate- and extended-release products	High	Moderate
Atenolol	Low-cost, familiar antihypertensive	High	Low to moderate
Bisoprolol	Beta-1 selectivity and heart-failure use	High	Moderate
Carvedilol	Beta and alpha blockade; heart-failure positioning	High	Moderate
Propranolol	Broad indications and multiple dosage forms	High	High

Acebutolol’s competitive disadvantage is limited market visibility compared with metoprolol and carvedilol. Its advantage is a differentiated pharmacologic profile and the possibility of serving patients for whom intrinsic sympathomimetic activity or ventricular-arrhythmia treatment remains relevant.

What revenue exposure exists for acebutolol products?

Revenue exposure is concentrated in generic volume rather than premium pricing. A manufacturer’s risk is therefore linked to:

• Number of active competitors
• Wholesaler and pharmacy substitution
• Reimbursement limits
• API cost
• Batch failure rates
• Supply interruptions
• Hospital-contract concentration
• Price erosion after additional ANDA entrants

A 200 mg and 400 mg portfolio can spread fixed regulatory and manufacturing costs across two strengths. However, the product should not be evaluated as a high-growth asset unless linked to a differentiated formulation, combination product, or supply-constrained market.

What generic launch scenarios exist?

Scenario 1: Standard capsule launch

This is the lowest-risk path. The applicant launches 200 mg and 400 mg immediate-release capsules using conventional excipients and a standard ANDA.

Commercial outcome: low development cost, rapid generic substitution, and significant price pressure.

Scenario 2: Supply-reliability launch

The applicant positions the product around dependable supply, dual API sourcing, and institutional contracts.

Commercial outcome: better volume stability and potential access to hospital or distributor agreements, but limited premium pricing.

Scenario 3: Differentiated formulation launch

The applicant develops a once-daily, sprinkle, or other patient-oriented product.

Commercial outcome: higher development and regulatory cost, with potential patent protection and differentiated reimbursement. Clinical and commercial validation become essential.

Scenario 4: Regional licensing launch

A rights holder licenses formulation, manufacturing, or geographic distribution rights to a regional generic company.

Commercial outcome: lower direct operating burden and faster market access, but royalty economics may be weak for a mature molecule.

What licensing deals are commercially plausible?

Licensing value is most likely in one of four areas:

1. A novel extended-release formulation.
2. A pediatric or geriatric dosage form.
3. A country-specific registration package.
4. A reliable API or finished-dose manufacturing arrangement.

A license covering only standard immediate-release capsules would have limited value unless it includes an approved product, established supply contracts, or an underpenetrated geographic market.

What geographic markets offer opportunity?

The United States offers a mature generic market with established regulatory expectations and limited product differentiation. Europe and other regulated markets may offer opportunities through decentralized or national registrations, provided the applicant meets local bioequivalence, pharmacopoeial, labeling, and pharmacovigilance requirements.

Emerging markets may provide volume opportunities but introduce risks involving price controls, tender competition, local manufacturing rules, currency exposure, and inconsistent reimbursement. Acebutolol’s mature status makes registration cost and supply economics more important than exclusivity in these markets.

Key Takeaways

• Acebutolol hydrochloride is a mature small-molecule beta blocker marketed mainly as 200 mg and 400 mg immediate-release capsules.
• The most practical excipient platform uses microcrystalline cellulose or lactose, a superdisintegrant, colloidal silicon dioxide, and magnesium stearate.
• Direct blending is the preferred first-line process if flow and content uniformity are acceptable.
• The conventional product has limited patent strength and no biosimilar risk.
• Generic commercial value depends on manufacturing cost, supply reliability, and market access.
• The strongest new-product opportunities are extended-release, sprinkle, geriatric, pediatric, and fixed-dose combination formulations.
• A formulation patent should claim measurable technical benefits rather than routine excipient substitution.
• Standard generic launch economics are likely to involve high substitution pressure and price erosion.
• Licensing is more attractive for differentiated delivery systems, regional registrations, or reliable supply platforms than for ordinary capsules.

FAQs

Is acebutolol hydrochloride still commercially viable?

Yes, as a low-cost generic or supply-reliability product. Premium value requires a differentiated formulation or combination product.

Which excipient is best for acebutolol hydrochloride capsules?

Microcrystalline cellulose is a practical primary diluent because it supports flow, blending, and capsule filling. The final choice depends on API properties and dissolution performance.

Can acebutolol hydrochloride be developed as an extended-release product?

Yes. Multiparticulate pellets, hydrophilic matrices, and other controlled-release technologies are technically available, but clinical and commercial differentiation would be required.

Does acebutolol hydrochloride have biosimilar competition?

No. Acebutolol hydrochloride is a chemically synthesized small molecule and is regulated through generic drug pathways rather than biosimilar pathways.

What is the highest-value intellectual-property strategy for acebutolol?

A patent covering a demonstrably improved delivery system, patient-use format, fixed-dose combination, or manufacturing process is more defensible than a patent covering conventional capsule excipients.

References

1. U.S. Food and Drug Administration. (n.d.). Sectral (acebutolol hydrochloride) capsules prescribing information.
2. U.S. National Library of Medicine. (n.d.). DailyMed: Acebutolol hydrochloride capsule labeling.
3. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2021). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA.